Biotech | September 22, 2021
Boehringer Ingelheim acquires Abexxa Biologics to advance its cancer research
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
